Intrauterine Device (IUD) Vaginal Mucosal Irritation Testing: Standards, Methods, and Evaluation

Vaginal mucosal irritation testing is a core biocompatibility study for intrauterine devices (IUDs), verifying that device materials, copper or drug-releasing components, and manufacturing residues do not provoke unacceptable local tissue reactions. Performed in accordance with ISO 10993-10, ISO 10993-23, and the GB/T 16886 series of standards, the intravaginal tolerance test is a key data element for regulatory submissions in China and major international markets. This article explains the test principle, sample preparation, scoring methodology, acceptance criteria, and typical applications.

Technical Overview

An intrauterine device (IUD) is a long-acting reversible contraceptive placed inside the uterine cavity through the cervix, with a retrieval thread that remains in contact with the vaginal canal. Depending on design, IUDs may be copper-bearing, hormone-releasing, or inert. Under ISO 10993-1, IUDs are classified as devices with prolonged or long-term mucosal membrane and tissue contact (exceeding 30 days), which makes local irritation and tolerability evaluation an essential part of the biological safety assessment.

The vaginal mucosal irritation test, formally known as the intravaginal tolerance test, evaluates the local tissue response of the vaginal mucosa after repeated exposure to extracts of the finished device. The vagina is used as the standard mucosal model because it shares structural and functional characteristics with the endometrial tissue that surrounds the device in situ, and because the insertion path and retrieval thread involve direct vaginal contact. The study is typically performed by accredited third-party laboratories under Good Laboratory Practice (GLP) conditions, with animal welfare managed in accordance with ISO 10993-2 and the principles of replacement, reduction, and refinement (3R).

• ISO 10993-1: Biological evaluation of medical devices — Evaluation and testing within a risk management process
• ISO 10993-10: Tests for irritation and delayed-type hypersensitivity
• ISO 10993-23: Tests for irritation
• ISO 10993-12: Sample preparation and reference materials
• ISO 10993-2: Animal welfare requirements
• GB/T 16886 series: Chinese national adoption of the ISO 10993 series
• ISO 7439: Copper-bearing intrauterine devices — requirements and tests

Testing Samples

Copper-Bearing IUDs

Copper IUDs consist of a polymer or stainless-steel frame carrying copper wire, sleeves, or collars. Copper ions released into surrounding fluids are deliberately cytotoxic to gametes but may also influence local tissue tolerance. Test samples should represent the final sterilized device, and the extraction design should account for the corrosion and ion-release behavior of the copper components as specified in ISO 7439.

Hormone-Releasing IUDs

Hormone-releasing IUDs incorporate a steroid drug core, typically a progestin, contained within polymer matrices and rate-controlling membranes. Biological evaluation must consider the device materials, residual monomers, catalysts, excipients, and degradation products in addition to the active pharmaceutical ingredient, since any of these can contribute to mucosal irritation.

Inert, Medicated IUDs, and Component Materials

Inert devices, such as stainless-steel rings or polymer frames, and medicated variants combining a drug with the frame may also be evaluated. Individual materials, such as frame resins, barium sulfate radiopaque fillers, suture threads, and packaging-contacting surfaces, can be assessed separately during material screening or failure investigations.

Extracts and Controls

Extracts are prepared in both a polar medium (physiological saline) and a non-polar medium (such as vegetable oil) following ISO 10993-12. Common extraction conditions are 37°C for 24 hours, with justified alternatives of 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour. Extraction ratios follow the standard, for example 0.2 g/mL on a mass basis or 6 cm²/mL on a surface-area basis for thin-walled materials. Each study includes a negative control (blank extraction vehicle) and, where method validation requires, a positive control using a documented mild irritant.

Testing Items

The vaginal mucosal irritation study evaluates both gross and histological endpoints to characterize the local tissue response:

• Macroscopic examination: scoring of erythema, eschar formation, and edema of the vaginal mucosa at necropsy
• Microscopic histopathology: grading of epithelial injury (ulceration, erosion, atrophy, or hyperplasia), leukocyte infiltration, vascular congestion, and edema on stained tissue sections
• Irritation index calculation: combined scoring of macroscopic and microscopic findings for the test extract compared with the negative control
• Complementary testing where justified: cytotoxicity screening per ISO 10993-5, chemical characterization and extractables analysis per ISO 10993-18, and ethylene oxide residue data per ISO 10993-7
• Optional in vitro adjuncts: reconstructed human vaginal epithelium tissue models used as screening tools within the ISO 10993-23 testing framework

Testing Methods

Animal Model and Administration

The study is typically performed in healthy, adult, nulliparous female rabbits, with female rats as an alternative model. Animals are randomized into treatment groups, commonly three to six animals per group depending on the protocol. A defined volume of test extract (typically 1 mL per animal) is instilled gently into the vaginal lumen once daily for a repeated dosing period, commonly five consecutive days, while blank vehicle is administered to the control group. Animals are observed daily for clinical signs such as discharge, swelling, or discomfort.

Necropsy and Tissue Evaluation

Approximately 24 hours after the final dose, animals are humanely euthanized and the vaginal tract is carefully exposed. The mucosa is inspected macroscopically and scored for erythema/eschar and edema on graded scales from 0 to 4. Vaginal tissues are then fixed in neutral buffered formalin, processed, sectioned, and stained with hematoxylin and eosin for microscopic evaluation. A veterinary pathologist scores the histological sections for epithelial integrity, inflammatory cell infiltration, vascular congestion, and edema.

Scoring, Calculation, and Acceptance Criteria

Macroscopic and microscopic scores from the test extract group are compared with those of the negative control group, and an overall irritation index is calculated from the mean scores. In general, responses that exceed the negative control by more than one scoring point are interpreted as evidence of irritation, subject to the acceptance criteria defined in the study protocol and agreed with the regulatory authority. Where histology indicates an irritant response, results are interpreted together with chemical characterization, cytotoxicity, and clinical use data within the framework of ISO 14971 risk management before a final biological safety conclusion is drawn.

Applications

Vaginal mucosal irritation testing supports the development and market access of IUDs across their full product lifecycle:

• Regulatory registration dossiers for contraceptive devices submitted to national medical device authorities, including biological evaluation documentation aligned with ISO 10993-1
• CE marking technical files under the European medical device regulation, where biocompatibility evidence is required for mucosal-contacting, long-duration devices
• Design change control, such as a new frame material, copper sleeve geometry, membrane formulation, sterilization method, or primary packaging that may alter the extractables profile
• Comparative material screening during research and development, allowing candidate polymers and components to be ranked by local tolerability
• Failure investigations and post-market safety support when adverse local tissue reactions are reported clinically
• Verification of processing changes, including ethylene oxide sterilization cycles, cleaning procedures, and residue limits

FAQ

Why is a vaginal irritation test required when the IUD is placed in the uterus?

IUDs are inserted through the cervix and their retrieval threads remain in permanent contact with the vaginal canal. More importantly, the vaginal mucosa is the accepted surrogate tissue model in ISO 10993-10 and ISO 10993-23 for evaluating the mucosal tolerability of devices that contact reproductive tract tissue for prolonged periods, making it the standard approach for this device category.

Which standards govern the test?

The primary standards are ISO 10993-10 and ISO 10993-23 for irritation test methods, ISO 10993-12 for sample preparation, and ISO 10993-2 for animal welfare. In China, the corresponding GB/T 16886 series applies. ISO 7439 provides additional product-specific requirements for copper-bearing devices.

What animals are used and how is dosing performed?

Healthy adult female rabbits are the preferred model, with female rats as an alternative. Test extract is instilled into the vagina once daily for a repeated dosing period, typically five consecutive days, followed by necropsy and tissue evaluation approximately 24 hours after the final dose.

How are results interpreted?

Macroscopic and microscopic scores from animals exposed to the test extract are compared with the negative control group. An irritation index is calculated from mean scores, and a test article is generally judged to have irritant potential when its response clearly exceeds the control, commonly by more than one scoring point, in accordance with protocol-defined acceptance criteria.

Can in vitro methods replace the animal study?

Reconstructed human vaginal epithelium models are increasingly used as screening tools and are encouraged by the ISO 10993-23 framework where scientifically valid. However, regulatory acceptance of standalone in vitro irritation data for long-term implantation-contact devices such as IUDs is still evaluated case by case, so the in vivo intravaginal tolerance test remains the reference method in most submissions.

What is the typical study timeline?

After extraction and sample characterization, the in-life phase generally takes one to two weeks, followed by histopathology and reporting. Most studies are completed within four to eight weeks, depending on laboratory capacity, protocol complexity, and any complementary chemical or cytotoxicity testing performed in parallel.